Home | Contact Us | Log In
(888) 789-6604
Report Stack
Advanced search
Account Detail 0 items in basket
Order History Total $
Saved Searches View Basket basket
Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
Publication Date Feb 2015
Product Type Report
Pages 1325
Single User License help $ 1995.00
Site User License help $ 2995.00
Corporate User License help $ 9995.00
 

Reportstack.com does not charge credit card fee, transaction charges, extra tax or VAT on any purchase.

"The Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading healthcare companies.
 
Revised and updated 11th edition, includes:
 
Trends in co-promotion and co-marketing deals
Co-promotion and co-marketing agreement structure
Co-promotion and co-marketing contract documents
Top co-promotion deals by value
Top co-marketing deals by value
Most active co-promotion dealmakers
Most active co-marketing dealmakers
 
This report provides details of the latest co-promotion and co-marketing agreements announced in the pharmaceutical, biotechnology and diagnostic sectors.
 
Fully revised and updated, the report provides details of co-promotion and co-marketing agreements from 2009 to end of December 2014.
 
The report provides a detailed understanding and analysis of how and why companies enter co-promotion and co-marketing deals. The majority of deals are multicomponent whereby the licensor retains either a right or option to co-promote/market the resultant product of the research collaboration. There are also numerous pure co-promotion/marketing deals whereby the products originator takes on a co-promotion/marketing partner in order to maximize a products presence in the marketplace.
 
The report provides a detailed understand and analysis of how and why companies enter co-promotion and co-marketing deals. The majority of deals are multicomponent whereby the licensor retains either a right or option to co-promote/market the resultant product of the research collaboration. There are also numerous pure co-promotion/marketing deals whereby the products originator takes on a co-promotion/marketing partner in order to maximize a products presence in the marketplace.
 
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
                               
This report contains a comprehensive listing of all co-promotion and co-marketing deals announced since 2009 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual co-promotion and co-marketing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
 
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
 
 Report scope        
Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report is intended to provide the reader with an in-depth understanding of the co-promotion and co-marketing trends and structure of deals entered into by leading biopharma companies worldwide.
 
Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics includes:
                                                       
Trends in co-promotion and co-marketing dealmaking in the biopharma industry since 2009
Analysis of co-promotion and co-marketing deal structure
Case studies of real-life co-promotion and co-marketing deals
Access to over 800 co-promotion and co-marketing deal records
Detailed access to actual co-promotion contract documents
The leading co-promotion and co-marketing deals by value since 2009
Most active co-promotion and co-marketing dealmakers since 2009
The leading co-promotion and co-marketing partnering resources
 
 In Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, the available contracts are listed by:
 
Company A-Z
Headline value
Stage of development at signing
Therapeutic area
Technology area
 
Each deal title links via Weblink to an online version of deal record as found in the Current Agreements deals and alliances database, providing easy access to each deal record on demand.
 
The Co-promotion and Co-marketing Partnering Terms and Agreements report provides comprehensive access to records for over 700 co-promotion and co-marketing deals. Analyzing actual contract agreements allows assessment of the following:
                                
What are the precise co-promotion and co-marketing rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law"

"Executive Summary
 
Chapter 1 – Introduction
 
Chapter 2 – Trends in co-promotion and co-marketing dealmaking
 
2.1. Introduction
2.2. Difference between co-promotion and co-marketing deals
2.3. Trends in co-promotion deals since 2009
2.4. Trends in co-marketing deals since 2009
2.4.1. When co-marketing can be useful
2.4.2. When co-marketing is the only option
2.5. Pure deals and multi-component deals
2.5.1. Attributes of pure co-promotion deals
2.5.2. Attributes of co-promotion in multi-component deals
2.6. Reasons for including co-promotion options in a deal
2.7. Uptake of co-promotion rights
2.8. Co-promotion rights as bargaining chips
2.9. Aligning partners to make the co-promote work
2.10 The future of co-promotion as part of multicomponent deals
 
Chapter 3 – Overview of co-promotion deal structure
 
3.1. Introduction
3.2. Pure versus multi-component co-promotion deals
3.3. Pure co-promotion agreement structure
3.3.1. Example co-promotion agreements
3.3.1.a. Case study 1: Allergan – MAP Pharmaceuticals – January 2011
3.3.1.b. Case study 2: Genzyme – Veracyte – January 2012
3.4. Co-promotion rights as part of a wider alliance agreement
3.4.1. Example co-promotion option clauses
3.4.1.a. Case study 3: Takeda Pharmaceutical– Orexigen Therapeutics– Sep 2010
3.4.1.b. Case study 4: Sanofi-Aventis – Merrimack Pharmaceuticals – Oct 2009
3.4.2. Example co-promotion right clauses
3.4.2.a. Case study 5: Takeda – Orexigen – September 2010
3.4.2.b. Case study 6: Abbvie – Receptos – March 2013
3.5. Embedded co-promotion rights enabling third party engagement
3.5.1. Example co-promotion clauses enabling third party engagement
3.5.1.a. Case study 7: Astellas – Ambit Biosciences – December 2009
 
Chapter 4 – Overview of co-marketing deal structure
 
4.1. Introduction
4.2. Co-marketing agreement structure
4.2.1. Example co-marketing agreements
4.2.1.a. Case study 8: AstraZeneca –Ironwood Pharmaceuticals– Oct 2012
4.3. Co-marketing rights as part of a wider alliance agreement
4.3.1. Example co-marketing right clauses
4.3.1.a. Case study 9: Lundbeck – Myriad Genetics – May 2008
 
Chapter 5 – Leading co-promotion deals
 
5.1. Introduction
5.2. Top co-promotion deals by value
5.3. Most active co-promotion dealmakers
5.4. Big pharma co-promotion deal activity
5.5. Big biotech co-promotion deal activity
 
Chapter 6 – Leading co-marketing deals
 
6.1. Introduction
6.2. Top co-marketing deals by value
6.3. Most active co-marketing dealmakers
6.4. Big pharma co-marketing deal activity
 
Chapter 7 – Big pharma co-promotion and co-marketing deals
 
7.1. Introduction
7.2. How to use co-promotion and co-marketing deals
7.3. Big pharma co-promotion and co-marketing agreement listings
 
Chapter 8 – Co-promotion agreement contracts directory 2009-2014
 
8.1. Introduction
8.2. Co-promotion partnering deals by company A-Z
8.3. By therapy area
8.4. By stage of development at signing
8.5. By technology area
 
Chapter 9 – Co-marketing agreement contracts directory 2009-2014
 
9.1. Introduction
9.2. Company A-Z
9.3. By therapy area
9.4. By stage of development at signing
9.5. By technology type
 
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering
Order Form – Upgrades to subscription access products
Order Form – Reports
 
 
TABLE OF FIGURES
 
Figure 1: Definition of co-promotion and co-marketing
Figure 2: Trends in co-promotion deal announcements, 2009-2014
Figure 3: Co-promotion deals signed at each phase of development, 2009-2014
Figure 4: Trends in co-marketing deal announcements, 2009-2014
Figure 5: Co-marketing deals signed at certain phases of development, 2009-2014
Figure 6: Situations where co-marketing can prove useful
Figure 7: Pure versus multi-component co-promotion deal announcements, 2009-2014
Figure 8: Stage of development at which pure and multi-component co-promotion deals are announced 2002-2014
Figure 9: Pure versus multi-component co-marketing deal announcements, 2009-2014
Figure 10: Stage of development at which pure and multi-component co-marketing deals are announced 2002-2014
Figure 11: Key components of a pure co-promotion deal
Figure 12: Key components of a multi-component co-promotion deal
Figure 13: Example deals where co-promotion options have been actively exercised, since 2000
Figure 14: Issues in implementing co-promotion agreements
Figure 15: Co-promotion agreements – what should a contract include?
Figure 16: Components of the co-promotion deal structure
Figure 17: Components of the co-marketing deal structure
Figure 18: Top co-promotion deals by value since 2009
Figure 19: Most active co-promotion dealmakers 2009-2014
Figure 20: Big pharma – top 50 – co-promotion deals 2009 to 2014
Figure 21: Big pharma co-promotion deal frequency - 2009 to 2014
Figure 22: Big biotech – top 50 – co-promotion deals 2009 to 2014
Figure 23: Big biotech co-promotion deal frequency - 2009 to 2014
Figure 24: Top co-marketing deals by value since 2009
Figure 25: Most active co-marketing dealmakers 2009-2014
Figure 26: Big pharma – top 50 – co-marketing deals since 2009
Figure 27: Big pharma co-marketing deal frequency - 2009 to 2014
 
Appendices
 
Appendix A1: Co promotion dealmaking- by companies A-Z
Appendix A2: Co promotion dealmaking- by stage of development
Appendix A3: Co promotion dealmaking- by therapeutic target
Appendix A4: Co promotion dealmaking- by technology type
Appendix B1: Co marketing dealmaking- by companies A-Z
Appendix B2: Co marketing dealmaking- by stage of development
Appendix B3: Co marketing dealmaking- by therapeutic target
Appendix B4: Co marketing dealmaking- by technology type"

Title Date Price
2014 Opportunities in the European Cancer Diagnostics Market
By Venture Planning Group
2014 Opportunities in the European Cancer Diagnostics Market” is a new five-country strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next f ...Read More
Sep 2013 $19700.00
2014 Opportunities in the European Clinical Chemistry and Immunodiagnostics Markets
By Venture Planning Group
2014 Opportunities in the European Clinical Chemistry and Immunodiagnostics Markets” is a new five-country strategic analysis of major business opportunities emerging in the clinical chemistry a ...Read More
Sep 2013 $19700.00
2014 Opportunities in the French Cancer Diagnostics Market
By Venture Planning Group
2014 Opportunities in the French Cancer Diagnostics Market is a new strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The re ...Read More
Sep 2013 $6700.00
2014 Opportunities in the French Clinical Chemistry and Immunodiagnostics Markets
By Venture Planning Group
“2014 Opportunities in the French Clinical Chemistry and Immunodiagnostics Markets” is a new strategic analysis of major business opportunities emerging in the French clinical chemistry an ...Read More
Sep 2013 $6100.00
2014 Opportunities in the German Cancer Diagnostics Market
By Venture Planning Group
2014 Opportunities in the German Cancer Diagnostics Market is a new strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The re ...Read More
Sep 2013 $6700.00
2014 Opportunities in the German Clinical Chemistry and Immunodiagnostics Markets
By Venture Planning Group
“2014 Opportunities in the German Clinical Chemistry and Immunodiagnostics Markets” is a new strategic analysis of major business opportunities emerging in the German clinical chemistry an ...Read More
Sep 2013 $6100.00
2014 Opportunities in the Global Cancer Diagnostics Market
By Venture Planning Group
2014 Opportunities in the Global Cancer Diagnostics Market  is a new seven-country strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next ...Read More
Sep 2013 $32500.00
2014 Opportunities in the Global Clinical Chemistry
By Venture Planning Group
“2014 Opportunities in the Global Clinical Chemistry and Immunodiagnostics Markets” is a new seven-country strategic analysis of major business opportunities emerging in the clinical chemi ...Read More
Sep 2013 $33500.00
2014 Opportunities in the Italian Cancer Diagnostics Market
By Venture Planning Group
2014 Opportunities in the Italian Cancer Diagnostics Market” is a new strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. Th ...Read More
Sep 2013 $6700.00
2014 Opportunities in the Italian Clinical Chemistry and Immunodiagnostics Markets
By Venture Planning Group
“2014 Opportunities in the Italian Clinical Chemistry and Immunodiagnostics Markets” is a new strategic analysis of major business opportunities emerging in the Italian clinical chemistry ...Read More
Sep 2013 $6100.00

  * Required field
Name *
E-mail *
Telephone 
Company *
Country *
Query 
 
   

  * Required field
Name *
E-mail *
Telephone 
Query 
 
   

Published By :  CurrentPartnering

For support please
contact:
US Toll Free
+1 888-789-6604
Asia Pacific
+91-9893555190
 
 
To receive alerts about
an update, future offers and discounts on this report, signup here.
Email ID
 

Companies


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Countries


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z